Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Aug;141(8):985-93.
doi: 10.1001/archderm.141.8.985.

Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial

Victoria L Brown  1 , Catherine L Atkins, Lucy Ghali, Rino Cerio, Catherine A Harwood, Charlotte M Proby
Affiliations
Clinical Trial

Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial

Victoria L Brown et al. Arch Dermatol. 2005 Aug.

Abstract

Objective: To evaluate the safety and efficacy of 5% imiquimod cream for cutaneous dysplasia in high-risk renal transplant recipients.

Design: A randomized, blinded, placebo-controlled study comparing treated with control skin.

Setting: A specialist organ transplant dermatology clinic.

Patients: Twenty-one high-risk patients with skin cancer with comparable areas of clinically atypical skin on dorsal hands or forearms.

Interventions: Imiquimod or placebo (randomly assigned) applied 3 times a week for 16 weeks to 1 dorsal hand or forearm, with 8 months of follow-up. At week 16, biopsy samples were collected from pre-assigned sites in the treatment and control areas and were examined for dysplasia.

Main outcome measures: The proportion of patients showing reduced numbers of viral and keratotic lesions and reduced histological severity of dysplasia in the treatment vs control areas at week 16, serum creatinine levels, and tumors developing in the study sites.

Results: Fourteen patients receiving imiquimod and 6 receiving placebo completed the study. Seven patients using imiquimod (1 taking placebo) had reduced skin atypia, 7 using imiquimod (none taking placebo) had reduced viral warts, and 5 using imiquimod (1 taking placebo) showed less dysplasia histologically. In 1 year, fewer squamous skin tumors arose in imiquimod-treated skin than in control areas. Renal function was not adversely affected.

Conclusions: Topical 5% imiquimod cream seems to be safe on skin areas up to 60 cm2 in renal transplant recipients. It may be effective in reducing cutaneous dysplasia and the frequency of squamous tumors developing in high-risk patients. Larger studies are required to confirm these results.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • HPV Carcinomas in Immunocompromised Patients.
    Reusser NM, Downing C, Guidry J, Tyring SK. Reusser NM, et al. J Clin Med. 2015 Jan 29;4(2):260-81. doi: 10.3390/jcm4020260. J Clin Med. 2015. PMID: 26239127 Free PMC article. Review.
  • Management of superficial basal cell carcinoma: focus on imiquimod.
    Raasch B. Raasch B. Clin Cosmet Investig Dermatol. 2009 Jun 11;2:65-75. doi: 10.2147/ccid.s3507. Clin Cosmet Investig Dermatol. 2009. PMID: 21436969 Free PMC article.
  • Topical Immunotherapy for Actinic Keratosis and Field Cancerization.
    Bernal Masferrer L, Gracia Cazaña T, Bernad Alonso I, Álvarez-Salafranca M, Almenara Blasco M, Gallego Rentero M, Juarranz de la Fuente Á, Gilaberte Y. Bernal Masferrer L, et al. Cancers (Basel). 2024 Mar 12;16(6):1133. doi: 10.3390/cancers16061133. Cancers (Basel). 2024. PMID: 38539468 Free PMC article. Review.
  • Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement.
    Massey PR, Schmults CD, Li SJ, Arron ST, Asgari MM, Bouwes Bavinck JN, Billingsley E, Blalock TW, Blasdale K, Carroll BT, Carucci JA, Chong AH, Christensen SR, Chung CL, DeSimone JA, Ducroux E, Escutia-Muñoz B, Ferrándiz-Pulido C, Fox MC, Genders RE, Geusau A, Gjersvik P, Hanlon AM, Olasz Harken EB, Hofbauer GFL, Hopkins RS, Leitenberger JJ, Loss MJ, Del Marmol V, Mascaró JM Jr, Myers SA, Nguyen BT, Oliveira WRP, Otley CC, Proby CM, Rácz E, Ruiz-Salas V, Samie FH, Seçkin D, Shah SN, Shin TM, Shumack SP, Soon SL, Stasko T, Zavattaro E, Zeitouni NC, Zwald FO, Harwood CA, Jambusaria-Pahlajani A. Massey PR, et al. JAMA Dermatol. 2021 Oct 1;157(10):1219-1226. doi: 10.1001/jamadermatol.2021.3180. JAMA Dermatol. 2021. PMID: 34468690 Free PMC article.
  • Viral Venereal Diseases of the Skin.
    Karagounis TK, Pomeranz MK. Karagounis TK, et al. Am J Clin Dermatol. 2021 Jul;22(4):523-540. doi: 10.1007/s40257-021-00606-7. Epub 2021 May 18. Am J Clin Dermatol. 2021. PMID: 34008162 Review.
See all "Cited by" articles

Publication types

MeSH terms